An investigation for investors in NASDAQ:KMPH shares was announced over potential securities laws violations by KemPharm Inc and certain of its directors and officers.
Investors who purchased shares of KemPharm Inc (NASDAQ:KMPH), have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether certain statements by KemPharm Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On May 5, 2016, KemPharm Inc announced that the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the FDA had reviewed and voted on Apadaz, determining by a vote of 16 to 4 that Apadaz should be approved for its proposed indication of the management of acute pain that requires an opioid, but voted 18 to 2 against inclusion of abuse deterrent labeling for the product.
On October 18, 2016, NASDAQ:KMPH shares closed at $4.10 per share.
Those who purchased NASDAQ:KMPH shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego